News
BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy
NICE has recommended routine use of Bristol-Myers Squibb's Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.
